United States - English - NLM (National Library of Medicine)

pierre fabre pharmaceuticals, inc. - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 4.28 mg in 1 ml - hemangeol oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. hemangeol is contraindicated in the following conditions: - premature infants with corrected age < 5 weeks - infants weighing less than 2 kg - known hypersensitivity to propranolol or any of the excipients [see description (11)] - asthma or history of bronchospasm - heart rate <80 beats per minute, greater than first degree heart block, or decompensated heart failure - blood pressure <50/30 mmhg - pheochromocytoma of 460 infants with proliferating infantile hemangioma requiring systemic therapy who were treated with hemangeol starting at 5 weeks to 5 months of age, 60% had complete or nearly complete resolution of their hemangioma at week 24 [see  clinical studies (14)]. safety and effectiveness for infantile hemangioma have not been established in pediatric

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide red; titanium dioxide; medium chain triglycerides; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. vinorelbine pierre fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. vinorelbine pierre fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

United States - English - NLM (National Library of Medicine)

pierre fabre usa inc. - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - sunscreen - tinted compact spf 50 helps prevent sunburn. - if used as directed with other sun protection measures ( see directions for use ), decreases the risk if skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

pierre fabre usa inc. - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - sunscreen - tinted compact spf 50 helps prevent sunburn. - if used as directed with other sun protection measures ( see directions for use ), decreases the risk if skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

pierre fabre usa inc. - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - sunscreen helps prevent sunburn. if used as directed with other sun protection measures ( see directions ), decreases the risk of skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

pierre fabre usa inc. - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - sunscreen • helps prevent sunburn • if used as directed with other sun protection measures ( see directions ), decreases the risk of skin cancer and early skin aging caused by the sun.